ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "NATALEE + a slew of FDA updates"
Episode Synopsis
FDA has been busy the last week approving:
-ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement
-osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC
-amivantamab + chemotherapy following progression on osimertinib (Mariposa-2)
-a subcutaneous formulation of atezolizumab
-isatuximab + VRD for multiple myeloma
-pembrolizumab + chemotherapy for metastatic pleural mesothelioma
-ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement
-osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC
-amivantamab + chemotherapy following progression on osimertinib (Mariposa-2)
-a subcutaneous formulation of atezolizumab
-isatuximab + VRD for multiple myeloma
-pembrolizumab + chemotherapy for metastatic pleural mesothelioma
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust